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Abstract
Oligogenic inheritance implies a role for several genetic factors in disease etiology. We studied oligogenic inheritance in
Parkinson’s (PD) by assessing the potential burden of additional rare variants in established Mendelian genes and/or GBA, in
individuals with and without a primary pathogenic genetic cause in two large independent cohorts totaling 7,900 PD cases
and 6,166 controls. An excess (30%) of cases with a recognised primary genetic cause had1 additional rare variants in
Mendelian PD genes, as compared with no known mutation PD cases (17%) and unaffected controls (16%), supporting our
hypothesis. Carriers of additional Mendelian gene variants have younger ages at onset (AAO). The effect of additional
Mendelian variants in LRRK2 G2019S mutation carriers, of which ATP13A2 variation is particularly common, may account for
some of the variation in penetrance. About 10% of No Known Mutation-PD cases harbour a rare GBA variant compared to
known pathogenic mutation PD cases (8%) and controls (5%), with carriers having earlier AAOs. Together, the data suggest
that the oligogenic inheritance of rare Mendelian variants may be important in patient with a primary pathogenic cause,
whereas GBA increases risk across all forms of PD. This study highlights the potential genetic complexity of Mendelian PD.
The identification of potential modifying variants provides new insights into disease mechanisms by potentially separating
relevant from benign variants and by the interaction between genes in specific pathways. In the future this may be relevant
to genetic testing and counselling of patients with PD and their families.
Introduction
Significant progress has been made in identifying genes linked to
Parkinson’s (PD). Mutations in several genes cause autosomal re-
cessive or dominant Mendelian PD (1) and common variation in
28 variants across 24 loci increase PD risk (2). However, 5–10% of
patients with PD, depending on the population, have a recog-
nized pathogenic Mendelian cause, and common variants only
contribute<5% of the genetic heritability (3), indicating that the
majority of genetic inheritance is unexplained. Polygenic inheri-
tance of common variants has been shown to be associated with
early-onset PD (4). There is also evidence that multiple rare vari-
ants in Mendelian genes may increase the risk of some diseases
in a non-Mendelian fashion in amyotrophic lateral sclerosis (5)
and schizophrenia (6). Here, we define Known Mutation-PD as PD
cases carrying a recognised high penetrance pathogenic muta-
tion regardless of family history. Using genotype and exome se-
quence data in two large independent case-control cohorts, we
therefore assessed the role of additional rare variants in PD genes
and GBA, in patients with PD with and without a known genetic
cause to determine if the inheritance of multiple variants might
contribute to the development of PD.
Results
A total of 181 rare variants within GBA and the established PD
Mendelian genes on the NeuroX platform passed our QC criteria
and were included in our analyses. Of these, 24 are known to be
pathogenic (4 LRRK2, 19 PARK2 and 1 VPS35), one variant is known
to increase PD risk (1 GBA; rs76763715), with the remaining 156
variants having no known role in PD. From the exome data 228
rare variants were included in the analyses, and included 19
known pathogenic variants (2 LRRK2, 12 PARK2, 2 PINK1, 2 SNCA
and 1 VPS35), three known risk variants (3 GBA), and 204 variants
of unknown significance. PCA based on variants shared between
the NeuroX and exome cohorts in relation to HapMap samples
failed to reveal hidden population stratification.
In the NeuroX data, 1.3% (89/6,647) of PD samples had estab-
lished PD-causing mutations (defining Known Mutation-PD
cases), comprising single mutations in autosomal dominant
genes (78 LRRK2, 1 VPS35) and biallelic mutations in autosomal
recessive genes (10 PARK2). Similarly, 1.4% (18/1,253) of cases in
the exome cohort harboured PD-causing mutations (9 LRRK2, 6
PARK2, 2 SNCA and 1 VPS35).
Focusing on the 107 Known Mutation-PD cases (Supplementary
Material, Table S1), we investigated the potential increased burden
of additional rare alleles in Mendelian PD genes separate to their
primary causal mutation. We first looked at the proportion of cases
carrying additional variants and observed that, after correction,
statistically more NeuroX Known Mutation-PD cases (16.9%) car-
ried additional variants compared to controls (9.2%; P¼ 0.019;
Pcorr¼0.048; Table 1). This finding was replicated in our second
dataset using exome data in which 33.3% of Known Mutation-PD
exomes samples harboured additional variants compared to 15.4%
of controls (P¼ 0.017). The role of additional Mendelian gene vari-
ants is corroborated by the increased burden of rare alleles in
Known Mutation-PD cases as compared to controls in the NeuroX
(OR¼ 1.70; 95% CI: 1.02–2.85; P¼ 0.043; Table 2). While this associa-
tion did not withstand correction for multiple testing (Pcorr¼0.065),
a similar pattern was also seen in the exome data (OR¼ 3.66; 95%
CI: 1.15–11.68; P¼ 0.028).
In the context of all PD cases, we then tested to see if this ob-
served enrichment was specific to Known Mutation-PD cases
only. The proportion of additional variant carriers in Known
Mutation-PD cases was higher than in No Known Mutation-PD
cases in both cohorts but neither were significantly different
(P¼ 0.058 and 0.143, respectively; Table 1). Similarly, the observed
enrichment of additional alleles in the NeuroX (OR¼ 1.49, 95%
CI: 0.90–2.46) and exome cohorts (OR¼ 1.51, 95% CI: 0.65–3.51;
Table 2) failed to reach significance.
We next examined whether the presence of additional
variants influences disease by modifying age at onset (AAO;
Table 3). AAO data were available for 74 (83.1%) and 15 (83.3%)
NeuroX and exome Known Mutation-PD samples, and for 5,713
(87.1%) and 1,130 (91.5%) No Known Mutation-PD samples.
Although Known Mutation-PD samples with additional variants
in the NeuroX cohort appeared to have had younger AAOs com-
pared to those without, of approximately six years, this did not
reach significance (P¼ 0.339). Younger AAOs, by approximately
four years, was also seen in the exome cohort and again, this
was not significant (P¼ 0.072).
As expected, LRRK2 was the most commonly mutated
Mendelian gene identified in this study. In the NeuroX cohort,
compared to controls, the majority of additional variants har-
boured by G2019S-positive LRRK2 cases in both cohorts were
within recessive PD genes (NeuroX: 14.7% vs. 5.7%, P¼ 0.007,
Pcorr¼0.007; Table 4). This was replicated in the exome but did
not reach independent significance (28.6% vs. 8.9%, P¼ 0.137).
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Interestingly, additional rare ATP13A2 variants appeared en-
riched in NeuroX LRRK2-positive cases (8.0% vs. 2.9%, P¼ 0.004,
Pcorr¼0.007). This enrichment was also seen in the exome co-
hort (14.3% vs. 1.7%, P¼ 0.017). Power constraints may have lim-
ited our ability to detect associations in the exome cohort, but
associations observed in the NeuroX withstood correction for
multiple testing. When considering all observed variation in
Mendelian PD genes, 8.5% of all LRRK2-positive cases compared
to 2.4% of controls harboured additional variants in ATP13A2
(P¼ 0.004). Taken together, the data have consistently indicated
an over-representation of additional variants in ATP13A2 in
LRRK2-positive cases. Due to very small numbers, the effect of
additional ATP13A2 variants in G2019S-carriers on AAO was
only assessed in the NeuroX data and no statistical difference
was observed (P¼ 0.178). There were no AAO differences in
ATP13A2 variant carriers across all PD cases or any of the
groups.
The LRRK2 G2019S mutation is more common in familial and
sporadic Ashkenazi Jewish (AJ) patients with PD, as compared
to other North American/European populations. Although we
did not have AJ ethnicity information for our PD cases, we re-
evaluated the data using AJ control samples. We specifically
evaluated the possibility that the ATP13A2 variants identified
might be relatively common in AJ individuals and that our re-
sults might relate to population stratification. We identified 12
different additional rare variants evenly distributed within six
different PD genes (Supplementary Material, Table S1), includ-
ing five different ATP13A2 non-Kufor-Rakeb syndrome (KRS)
variants, in our LRRK2-positive cohort. We first investigated
these variants using minor allele frequency (MAF) data from
Table 1. Number of Parkinson’s cases and controls in the NeuroX and exome cohorts harbouring additional rare variants in Parkinson’s
Mendelian and risk genes
Number of additional variants NeuroX (Cases ¼ 6,647; Controls ¼ 5,693) Exome (Cases ¼ 1,253; Controls ¼ 473)
Mendelian GBA Mendelian GBA
N Freq N Freq N Freq N Freq
Known Mutation-PDa
0 74 0.8315 82 0.9213 12 0.6667 18 1.0000
1 15 0.1685 7 0.0787 5 0.2778 0c –
2 0 – 0 – 1 0.0556 0c –
No Known Mutation-PDb
0 5,881 0.8968 5,995 0.9142 1,031 0.8348 1,108 0.8972
1 634 0.0967 551 0.0840 181 0.1466 126 0.1020
2 38 0.0058 12 0.0018 20 0.0162 1 0.0008
3 5 0.0008 0 2 0.0016 0 –
4 0 – 0 – 1 0.0008 0 –
Controls
0 5,169 0.9079 5,429 0.9536 400 0.8457 451 0.9535
1 499 0.0877 262 0.0460 69 0.1459 22 0.0465
2 24 0.0042 2 0.0004 4 0.0085 0 –
3 1 0.0002 0 –
Abbreviations: Freq, frequency; GBA, Glucocerebrosidase; N, number of samples; PD, Parkinson’s disease.
aSamples with a known genetic cause identified.
bSamples without a known genetic cause.
cNo carriers of risk alleles observed in the known mutation-PD samples.
Table 2. Investigation of additional rare alleles in known Parkinson’s Mendelian and risk genes in the NeuroX and exome cohorts
N Mendelian genes GBA
OR (95% CI) P OR (95% CI) P
NeuroX
Known Mutation-PDa vs. Controls 89/5,693 1.70 (1.02–2.85) 0.043 1.88 (0.86–4.10) 0.112
No Known Mutation-PDb vs. Controls 6,558/5,693 1.14 (1.02–1.28) 0.017 1.96 (1.69–2.28) 8.00E–19
Known Mutation-PD vs. No Known Mutation-PD 89/6,558 1.49 (0.90–2.46) 0.125 0.94 (0.44–2.04) 0.881
Exome
Known Mutation-PDa vs. Controls 18/473 3.66 (1.15–11.68) 0.028 0c –
No Known Mutation-PDb vs. Controls 1,235/473 1.05 (0.80–1.40) 0.711 2.39 (1.47–3.90) 0.0005
Known Mutation-PD vs. No Known Mutation-PD 18/1,235 1.51 (0.65–3.51) 0.343 0c –
Abbreviations: CI, confidence intervals; N, Number of samples per group; OR, odds ratio; PD, Parkinson’s disease; P, logistic regression P-value correcting for gender,
capture (exome only), population differences and platform (combined analysis only).
aSamples with a known genetic cause identified.
bSamples without an identified genetic causal.
cNo carriers of risk alleles observed in the Known Mutation-PD samples.
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3,044 AJ non-inflammatory bowel disease control samples to
compare observed allele frequencies (Supplementary Material,
Table S2; IBD Exomes Portal, Cambridge, MA; http://ibd.broadin
stitute.org; date last accessed June 2016). All but one (ATP13A2
p.P1100L, rs201756175) of the rare variants enriched in our
LRRK2-positive samples were either not observed or were ob-
served at lower/similar frequencies in the AJ controls as com-
pared to the ExAc database. Removal of p.P1100L (which was
only seen in the NeuroX cohort, and was more common in AJ
controls) did not affect the results. Known Mutation-PD NeuroX
samples (14.6%) still had more additional rare variants com-
pared to No Known Mutation-PD (10.2%) and controls (9.0%),
and ATP13A2 variants were still over-represented in LRRK2
G2019S carriers affected by PD. Secondly, using AJ defined
MAFs, we assessed the burden of rare variants using individual
level data from 318 AJ inflammatory bowel disease patients un-
affected by PD (Supplementary Material, Table S6). All variants
enriched in the Known Mutation-PD cases were rare or not ob-
served in the 318 AJ samples (Supplementary Material, Table
S2). Although underpowered, a smaller proportion of carriers of
rare variants across all PD genes was also seen in the AJ control
samples (18.9%; 60/318) as compared to the Known Mutation-PD
samples. As in the initial analysis, a similar excess of ATP13A2
variants was seen in the LRRK2 G2019S PD cases compared to AJ
control samples (14.3% vs. 5.0%; 16/318). Overall, our analysis
does not suggest that the observed effects were due to popula-
tion stratification but further analysis with larger AJ control
datasets is recommended.
While no GBA variants were seen in the Known Mutation-PD
exome group, we observed a higher proportion of carriers
of additional GBA variants in the Known Mutation-PD
NeuroX group compared to controls (7.9% vs. 4.7%; P¼ 0.106).
Significantly increased proportions were also seen for the No
Known Mutation-PD NeuroX samples compared to controls
(P¼ 1.63E-18; Table 1). This association was still significant after
correction (Pcorr¼4.80E-18) and was replicated in the exome
data (P¼ 0.0005) therefore indicating that this effect was not
confined to Known Mutation-PD. Evidence for allelic enrich-
ment was observed for both Known Mutation-PD and No
Known Mutation-PD as compared to controls in both cohorts
(Table 2) suggesting that GBA variants are important across all
forms of PD. There was a strong effect of GBA on AAO with
NeuroX No Known Mutation-PD carriers of GBA variants having
significantly lower AAOs than those without (on average 2.3
years; P¼ 0.0003, Pcorr¼0.0005). A trend in the same direction
was noted for the exome cohort (Table 3). Specific biallelic GBA
mutations cause Gaucher’s disease (GD). No sample appeared to
have GBA-related GD. Interestingly the majority of the GBA risk
variants in the NeuroX Known Mutation-PD group were all het-
erozygous for GD-causing mutations (5/7; 71.4%) as opposed to
No Known Mutation-PD cases (64.1%; 361/563) and controls
(164/264; 62.2%). Despite small numbers, NeuroX Known
Mutation-PD samples harbouring single GD-associated GBA mu-
tations appeared to have an excess of additional variants across
all Mendelian genes studied (42.9%) (Supplementary Material,
Table S3) as well as enrichment of additional ATP13A2 variants
(14.3%) compared to No Known Mutation-PD cases (2.5%, P¼ 0.
147) and controls (1.2%, P¼ 0.128) (Supplementary Material,
Table S4).
Discussion
Here, we show in two large independent cohorts that PD cases
with an established Mendelian genetic cause have an excess of
additional rare variants of currently unknown significance in PD
Table 3. Average age of onset of Parkinson’s cases that harbour additional variants in known Mendelian and risk genes in the NeuroX and
exome cohorts
NeuroX Exome
Genes With Without Coeff (95% CI) P With Without Coeff (95% CI) P
All PD
Mendelian 61.4 61.3 0.06 (0.98; 1.09) 0.916 41.8 43.3 1.34 (2.98; 0.30) 0.109
GBA 59.3 61.5 2.10 (3.25; 0.95) 0.0003 42.4 43.1 0.31 (2.28; 1.67) 0.762
Known Mutation-PDa
Mendelian 56.8 62.7 3.78 (11.62; 4.06) 0.339 38.3 42.3 16.54 (35.09; 2.01) 0.072
GBA 64.6 61.6 0.23 (11.75; 11.29) 0.968 0c 0c – –
No Known Mutation-PDb
Mendelian 61.5 61.3 0.16 (0.89; 1.20) 0.767 41.9 43.3 1.29 (2.94; 0.37) 0.127
GBA 59.2 61.5 2.16 (3.31; 1.00) 0.0003 42.4 43.1 0.31 (2.29; 1.66) 0.755
For each group, differences in the average age at onset were assessed by comparing cases harbouring additional variants to those without.
Abbreviations: CI, confidence interval; Coeff, regression coefficient; GBA, Glucocerebrosidase; PD, Parkinson’s disease; P, Linear regression P-value correcting for popu-
lation, gender and capture (exome only);.
aSamples with a known genetic cause identified.
bSamples without a known genetic cause.
cNo carriers of risk alleles observed in the Known Mutation-PD samples.
Table 4. Enrichment of rare additional variants within known reces-
sive Parkinson’s disease (PD) genes in LRRK2-mutation positive PD
cases
NeuroX Exome All variants
Cases
Total LRRK2 mutation positive 78 9 87
Total G2019S positive 75 7 82
With additional rare variants 13 (17.3%) 2 (28.6%) 15 (18.3%)
In recessive PD genes 11 (14.7%) 2 (28.6%) 13 (15.9%)
In ATP13A2 6 (8.0%) 1 (14.3%) 7 (8.5%)
Controls
In recessive PD genes 323 (5.7%) 42 (8.9%) 379 (6.2%)
In ATP13A2 163 (2.9%) 8 (1.7%) 146 (2.4%)
Abbreviations: ATP13A2, ATPase 13A2; G, glycine; LRRK2, Leucine-rich repeat ki-
nase 2; PD, Parkinson’s disease; S, serine.
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genes as compared to No Known Mutation-PD and controls.
Carriers of additional rare variants also have a lower AOO by as
much as 6 years in NeuroX and 4 years in exome data. Although
neither finding was statistically significant, likely due to small
number constraints, this provides preliminary evidence for the
modifying effect of variants in additional genes in Mendelian
PD. Overall, 33.3% of Known Mutation-PD cases have additional
rare variants within established PD-causing genes compared to
controls (15.6%) and No Known Mutation-PD cases (16.5%).
Taken together the data, generated on different platforms
(NeuroX rare variant genotyping chip and exome sequencing)
that detected different numbers of variants, consistently pro-
vides evidence of possible oligogenic inheritance in Known
Mutation-PD. Differences in the same direction between Known
Mutation-PD and No Known Mutation-PD cases in both the
exome and NeuroX cohorts suggest that the burden of addi-
tional rare variants might have a more prominent role in car-
riers of known high-penetrant mutations. In contrast, GBA does
not have a specific effect in Known Mutation-PD as both PD
groups had a comparable increase in GBA variant frequency as
compared to controls.
Several large-scale studies have reported that the LRRK2
G2019S mutation has reduced penetrance as well as phenotypic
and/or pathological heterogeneity. Any modifying factors, aside
from age, are unknown (7), and we infer that other genetic or
environmental factors may influence LRRK2-disease. We found
an enrichment of additional rare variants in recessive PD genes
in LRRK2-cases in both cohorts and upon combining datasets.
When considering all additional variants for both cohorts to-
gether, we identified that 6.2% of controls harbour an additional
variant in a recessive PD gene, compared to 15.9% of LRRK2-
positive Known Mutation-PD cases. Although underpowered,
together the data consistently suggest that the presence of addi-
tional rare variants of unknown significance within recessive
PD genes may influence penetrance. Typically, LRRK2 mutation
testing is offered to familial dominant cases or those from high-
risk populations (8). Extending screening of LRRK2-positive
cases to all known Mendelian PD genes as routine may uncover
potential oligogenic variants and assist in elucidating the
evident disease heterogeneity. Assessing potential oligogenic
inheritance in a larger number of clinically unaffected LRRK2
PD-mutation carriers would provide greater insight into the
roles of additional variants in PD.
Lysosomal dysfunctional in PD is well established, with sev-
eral PD genes having a primary lysosomal function (9). Enlarged
lysosomes are a common phenotype in LRRK2-positive PD, as is
increased lysosomal ATP13A2 expression (10). ATP13A2 muta-
tions cause KRS (MIM:606693). Additional variants enriched in
G2019S-positive cases appear to cluster towards the C-terminus
of isoform 3 of ATP13A2 (NM_001141974) (Supplementary
Material, Fig. S1). This has implications for cellular assessments
in that studies on this gene in PD may need to be extended to all
isoforms. While not causal for KRS, these variants may affect
ATP13A2 function and modify existing disease in G2019S car-
riers. A similar enrichment of additional ATP13A2 variants in
GBA variant carriers was also observed. While the overlap of
GBA and ATP13A2 remains to be elucidated, our identification of
a specific overlap between GBA, ATP13A2 and LRRK2 points to a
convergence of ATP13A2 and LRRK2 in lysosomal function in PD.
A range of genetic variants appear to modulate AAO. We
have previously described a role of both genome-wide signifi-
cant and polygenic common variants in modulating PD AAO (4).
In this work, we show that there is a reduced AAO in carriers of
GBA mutations in PD cases in both cohorts and upon combining
data sets together. We now have clear evidence that rare GBA
risk variants and common GWAS-identified variants influence
disease AAO. Further studies in larger datasets are needed to in-
vestigate the effect of rare variants in Mendelian genes and to
fully explore the interplay between rare and common variants.
Population stratification is a significant concern, particularly
when looking at individuals with a common founder mutation
such as LRRK2 G2019S. Together, the observed diversity of
ATP13A2 variants, the observed rarity of the additional variants
observed in the LRRK2-positive samples within two AJ cohorts
and, as in the initial analysis, the similar magnitude of excess of
ATP13A2 variants in LRRK2 G2019S cases as compared to AJ con-
trols, suggest that our results are not due to population stratifi-
cation. However, further studies in large well-defined AJ
population cohorts and in LRRK2 G2019S families with variable
penetrance are needed.
The results here are likely to be conservative estimates of
oligogenic inheritance in PD. We have not comprehensively
studied all incident Known Mutation-PD cases, not all patho-
genic variants were included on the NeuroX platform, and the
identification of Mendelian copy number variants (CNVs) was
limited. The exome may have captured many more singletons
which may be driving the observed results, while fewer repre-
sented variants on the NeuroX platform may have contrib-
uted to the observed power constraints. Additional studies
are needed to help elucidate the role of additional PD gene
variants in disease aetiology. The NeuroX CNV carrier fre-
quency is lower than other studies (11), and this will have at-
tenuated case-control differences. The variants were not
confirmed by Sanger sequencing; however, any systematic
bias in each cohort should be present for all samples.
Similarly, not all CNVs were validated using multiplex
ligation-dependent probe amplification (MLPA); however, all
13 samples that were available had the PennCNV-identified
CNVs successfully validated.
In conclusion, we demonstrate that about 30% of Known
Mutation-PD cases carry additional rare variants in PD genes
compared to No Known Mutation-PD cases (16%) and controls
(15%), and that carriers have a lower AAO. Although based on a
large number of samples, only a small proportion carried pri-
mary pathogenic mutations and so our study is underpowered.
Our findings, which were consistent across both cohorts provide
evidence that the oligogenic inheritance of variants may be im-
portant in the development of PD. By acting as potential disease
modifiers, additional rare variants in Mendelian genes, particu-
larly ATP13A2, may account for some of the observed AAO het-
erogeneity in LRRK2-positive cases. As previously described,
rare GBA variants are an important risk factor across all forms
of PD. Further interpretation of oligogenic inheritance particu-
larly in families with apparent reduced penetrance is needed.
Although not all rare variants will have a biological effect, this
study annotates a new set of variants that may influence dis-
ease development. The underlying reasons for the observed ex-
cess of additional variants in Known Mutation-PD cases as
opposed to No Known Mutation-PD cases, where additional var-
iants would be expected to also influence AAO, is unclear. This
distinction between Known Mutation-PD and No Known
Mutation-PD suggest that selective cellular pathways may be
important in individuals with Known Mutation/Mendelian PD.
Further work into the functional effect of these variants in
model systems is needed. The clustering of modifying genetic
factors in specific gene families in PD subgroups may provide
further insights into pathways important in PD. In the future,
genetic counselling in PD families may incorporate the potential
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disease modifying role of additional variants in order to im-
prove the advice given to at-risk individuals.
Methods and Materials
We first assessed high-quality genotype data derived from the
NeuroX chip on 6,647 PD cases and 5,693 controls from the
International Parkinson’s Disease Genomics Consortium
(IPDGC; dbGaP Study Accession number: phs000918.v1.p1).
Sample collection and variant genotyping are described else-
where (12). We then used exome sequencing data on 1,253 inde-
pendent PD cases and 473 controls, also from the IPDGC, as a
replication data set. These cohorts were assembled for the dis-
covery of new disease genes, and in some cases, samples with
known disease genes were not submitted for analysis. The
exome sequence samples were primarily derived from patients
with early-onset PD.
Using annotated MAF data from 1000 Genomes Project
(http://www.1000genomes.org/; date last accessed April 2015)
and NHLBI GO Exome Sequencing Project (https://evs.gs.wash
ington.edu/EVS/; date last accessed April 2015), all rare
(MAF< 1%) variants (excluding synonymous) within ten known
Mendelian PD genes and GBA (Supplementary Material, Table
S5) were extracted and assessed from NeuroX and exome data.
Variants and samples with>5% missing calls were excluded.
Population outliers, based on principal components analysis
(PCA) using HapMap population data, were also removed. Rare
CNVs within PARK2 were called from the NeuroX data using
PennCNV (13). All CNVs spanned a minimum of 10 variants,
were then visually confirmed and validated using MLPA where
possible.
We specifically assessed the possibility of oligogenic inheri-
tance in the pathogenesis of PD. This was done by investigating
whether PD cases who harboured known primary Mendelian
mutations, i.e well-established pathogenic dominant allele(s) or
biallelic recessive alleles/CNVs (Known Mutation-PD cases), car-
ried an excess of additional variants within (i) established
Mendelian PD genes and (ii) GBA, compared to PD cases without
a known Mendelian cause (which we refer to as No Known
Mutation-PD) and unaffected controls. Pathogenic mutations
were defined as those established mutations stringently defined
as causing PD within the literature according to OMIM (http://
omim.org/; date last accessed June 2016) and/or the Parkinson
Disease Mutation Database (http://www.molgen.vib-ua.be/
PDMutDB/; date last accessed June 2016).
Logistic regression was used to examine differences in the
proportion of carriers of additional variants in Mendelian
genes or GBA between Known Mutation-PD cases, No Known
Mutation-PD cases, and unaffected controls. To assess allelic
enrichment between groups, we summed the additional al-
leles per individual and remodeled the logistic regression.
Within each group (Known Mutation-PD and No Known
Mutation-PD), we compared carriers of additional variants to
those without using linear regression to investigate the impact
of additional variants on AAO. Fisher’s exact test was used to
test differences in the number of LRRK2-positive PD cases with
additional variants, when considering all observed variation,
in both cohorts combined. To improve the power to detect
enrichment, we also combined datasets while limiting
these analyses to variants common to both platforms. The fol-
lowing covariates were used in all the above analyses: gender,
capture metrics (exome only), PCA components (1–4) and
platform (for combined analyses only). To account for
multiple testing issues we applied a false discovery rate (FDR)
threshold<0.05 (14).
Supplementary Material
Supplementary Material is available at HMG online.
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